Member Companies

Harlem Biospace is a hub for biotech innovators in NYC, and the core of this community are the companies that call Hb home. Through a competitive application cycle every six months we select some of the region’s most promising early stage ventures to work from the lab. Our inaugural batch of companies includes:

   Enabling clients to accelerate commercialization of gene based products.

AfriVax, Inc. is a Contract Research company (CRO) that researches, tests, and manufactures biopharmaceutical products using molecular technologies. The company’s mission is to develop the next generation of safe, low-cost products to aid in the fight against human and animal diseases.

AfriVax uses bioinformatics and protein expression technologies to develop gene-based products such as vaccines, therapeutic proteins, rMAbs, diagnostic reagents and custom research products. We offer molecular design and engineering to improve your DNA, RNA or protein molecular discoveries and support your product development through the translational research stage for faster, safer and less expensive commercialization.

Team

SONY DSCEluemuno Richard Blyden, Ph.D. (Founder/CEO) – Dr. Blyden has worked in Europe, Africa, and the USA over the past 17 years developing biotechnologies applicable in developing countries. As CEO, he is responsible for the overall leadership and strategic guidance of the company. He has previously been involved in the start-up of medical imaging, recombinant biotechnology, and genomics software companies. Dr. Blyden holds a Ph.D. in Molecular Genetics from Cambridge University, UK and a B.Sc. cum laude in Biological Sciences from East Anglia University, UK. He works in the global health community at an international level as an entrepreneur, educator, researcher and consultant for biotechnology, food security and influenza pandemic preparedness. He is the inventor of the Phytopod.

SONY DSCVictor Jonathan Temple M. Sc.; Ph.D. (Chief Science Officer) – Victor is a biochemist with special interest in Nutrition, Toxicology and Biotechnology. He is an expert in the use of laboratory analytical techniques such as: PCR, HPLC, EIA, AAS, ICP-MS, etc. Successfully completed several high quality research funded projects in Micronutrients, Endocrinology, Drug Discovery, Toxicology and Genetic Fingerprinting for Forensic Data Base. Specific areas of interest include molecular mechanism of anti-cancer drug action, cancer chemotherapy and drug DNA interactions, effects of drugs on gene expression, DNA repair and apoptosis, gene therapy, human DNA repair systems, cancer genetics, human genetics, parasite genetics, microbial genetics and bioactive compounds.

Collapse Company

    Targeting the Neuronal Cytosol for Applications in Neuromuscular Medicine, and Drug Delivery.

CytoDel™, has developed patented compositions that enables Botulinum neurotoxins (BoNTs, such as the BOTOX® product marketed by Allergan) to be bioengineered for improved performance in established pharmaceutical markets, and for drug delivery to the neuronal cytosol. Two products are being actively developed: Cyto-111, designed to deliver an antidote to BoNT poisoning (a biodefense need) to the cytosol of neurons using a “trojan horse” approach; and Cyto-012, developed as a “safer” BoNT for the treatment of spasticity disorders and for aesthetic medicine.

Team

SONY DSC Dr. Philip Band (Scientific Director) – Co-inventor of the CytoDel™ technology and a co-founder of CytoDel™. Dr. Band has extensive bench-to-bedside experience in biotechnology startups as former Research Vice President of Biomatrix, an NYSE company acquired by Sanofi/Genzyme. Dr. Band is currently Director of the Center for Clinical Research, NYU-Hospital for Joint Diseases, and an Associate Research Professor in the Departments of Orthopaedic Surgery, Biochemistry and Molecular Pharmacology.

SONY DSCDr. Edwin Vazquez-Cintron (Director of Research) – Co-inventor of the CytoDel™ technology and a co-founder of CytoDel™. Edwin holds a Master’s degree in Pathobiology and a Doctorate in Immunology from the Sackler Institute of Biomedical Science at NYU’s School of Medicine. Edwin has participated in all aspects of CytoDel’s™ birth and continues to co-manage its development. Edwin is also an Adjunct Research Professor at City College of New York and has served as a Science Advisor to the Editorial and Production team at TEDMED. Edwin is currently finishing his post-doctoral research focused in Biochemistry and Molecular Pharmacology at NYU’s School of Medicine and transitioning into CytoDel™.

SONY DSCDr. Konstantin Ichtchenko (Senior Scientific Advisor) Dr. Ichtchenko is a widely acknowledged expert on protein engineering and neuronal trafficking. Past achievements of Dr. Ichtchenko include expression, purification and study of molecular mechanisms of complex proteins in their native state, done in collaboration with four Nobel laureates, Dr. Thomas Südhof, Dr. Johann Deisenhofer. Dr. Joseph Goldstein, and Dr. Michael Brown. The Ichtchenko lab currently concentrates on expressing recombinant derivatives of Botulinum neurotoxins (BoNTs) that retains the native toxin’s unique trafficking properties. This creates translational opportunities for both therapeutic and biodefense applications, currently funded by $6.5 million NIH multi-center grant. Dr. Ichtchenko is currently Assistant Professor in the Department of Biochemistry and Molecular Pharmacology, NYU Langone Medical Center.

Catherine Banat (Co-founder and President) – Catherine has extensive experience in finance services with expertise in financing, structuring, strategy, business development, and capital raising. Currently with the New York City Retirement System, she has worked for Goldman, Sachs, Lehman Brothers, JP Morgan, and Paloma Partners. She holds an M.B.A. from Columbia University and a B.S.E. from the Wharton School.

Collapse Company

   Developing a novel series of small molecule therapeutics for suppressing tumors.

Dual Therapeutics is a highly innovative R&D company focused on the development of a novel series of small molecule activators of the tumor suppressor protein phosphatase 2A to simultaneously block several growth and survival pathways driving multiple cancers including prostate, lung, and acute lymphoblastic leukemia.

The technology originates from the work of Dr. Goutham Narla, a Harrington Distinguished Scholar at University Hospitals Case Medical Center, Dr. Michael Ohlmeyer, Associate Professor of Structural and Chemical Biology at the Icahn School of Medicine, and Dr. Matthew Galsky, Associate Professor of Medicine and Director of Genitourinary Medical Oncology at the Icahn School of Medicine. The technology was licensed from Mount Sinai Medical Center in New York City.

Team

SONY DSC

Matthew Galsky, MD (Founder) – Matthew Galsky, MD, is a medical oncologist, Associate Professor of Medicine, and the Director of Genitourinary Medical Oncology at the Icahn School of Medicine at Mount Sinai. Dr. Galsky has extensive experience in the design and conduct of early phase clinical trials for anticancer therapies. He received his training in internal medicine at Beth Israel Deaconess Medical Center/Harvard Medical School and in Medical Oncology at Memorial Sloan-Kettering Cancer Center where he was subsequently on faculty.


SONY DSC

Goutham Narla, MD, PhD (Founder) – Dr. Narla is a medical geneticist and a physician scientist at University Hospitals / Case Western Reserve University and a Harrington Distinguished Scholar, with expertise in cancer genetics and mouse xenograft and transgenic models of prostate, lung, and other cancers with over 47 publications in the field.

He is the recipient of early career award from the Howard Hughes Medical Institute (HHMI) along with Harold Lamport Biomedical Research Prize. He was recently award a grant from the Howard Hughes Medical Institute to continue his work on the molecular mechanisms underlying prostate cancer metastasis.

SONY DSC

Michael Ohlmeyer, PhD (Founder) – Michael runs a medicinal chemistry laboratory at Mount Sinai Medical Center and has 15 years of experience in the biopharmaceutical industry, including start-ups based on academic spin-outs working in the area of hit-to-lead and lead optimization medicinal chemistry, including extensive use of and contacts with contract research organizations.



SONY DSC

Yiannis Ioannou, PhD (Founder) – Yiannis is a molecular geneticist and cell biologist. He is Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and is an expert in neurodegenerative storage disorders. He has more than 25 years of experience in drug development for rare diseases and he is the co-developer of the FDA-approved therapy for Fabry’s disease.


Collapse Company

   Grow Your Own Bone.

EpiBone is a Columbia University spin-out focused on producing fully functional, anatomically-precise, patient specific, living bone tissue from patients’ own stem cells. EpiBone’s engineered, living bone is suitable for anatomically challenging defects that severely debilitate the patient, functionally and psychologically, and limit quality of life. These defects, whether rendered by trauma, congenital abnormalities, cancer, or aesthetic reconstruction, require precise, functional, patient-specific bone. EpiBone employs breakthrough, proprietary methods, devices and systems for bone tissue engineering using bioreactors (i.e. custom designed advanced cell culture systems for 3-D tissues). EpiBone’s technology allows the configuration of complex 3-D grafts, as well as controlled perfusion and live imaging capabilities. These methods, devices and systems are protected by a suite of issued and pending patents. In addition, EpiBone employs substantial technical know-how, and is led by a team of world-class scientists and clinicians, and is advised by Columbia University Professors, Dr. Gordana Vunjak-Novakovic and Dr. Sidney Eisig.

Team

SONY DSC

Nina Tandon (CEO and Co-Founder) – Nina obtained her bachelor’s degree in electrical engineering from the Cooper Union, a Master’s in Bioelectrical Engineering at MIT, and a PhD in Biomedical Engineering along with an MBA at Columbia University, NY. She is a TED Senior Fellow, Staff Associate Postdoctoral Researcher in the Laboratory for Stem Cells and Tissue Engineering, Columbia University, and adjunct professor of Electrical Engineering at the Cooper Union. Nina’s PhD research focused on studying electrical signaling in the context of tissue engineering, and has worked with cardiac, skin, bone and neural tissue. Nina spent her early career in telecom (Avaya Labs) and transitioned into biomedical engineering via a Fulbright scholarship in Italy. After completing her PhD at MIT and Columbia, she consulted at McKinsey and Company, but since 2010 has continued her work in tissue engineering. Nina has published 10 journal articles (cited >300 times, H=9), 6 book chapters and has 3 patents. She’s published in Nature Protocols and Lab on a Chip, spoken three times at TED, and Fast Company Magazine named her one of their 100 most creative people in business, 2012. In her spare time, she enjoys practicing yoga, playing with puppies, running slowly, baking cookies, laughing with her niece, and avoiding folding the laundry.


SONY DSC

Sarindr Bhumiratana (CSO and Co-Founder) – Originally from Bangkok, Thailand, Sarindr (Ick) moved to the US to pursued his education in Biomedical Engineering. He obtained his bachelor’s degree from Northwestern University, Master’s at University of Michigan-Ann Arbor, and Ph.D. and post-doc at columbia University. His Ph.D. research focused on bone and cartilage tissue engineering from adult mesenchymal stem cells. He is an author of more than 15 journal articles related to bone and cartilage tissue engineering (cited >270 times), 4 book chapters, and has 2 patents. He has been invited to speak at several special seminar at different Universities and at FDA Bone seminar workshop. In his spare time, he enjoys all sort of sports such as soccer, basketball, rock climbing, badminton, and snowboarding. He likes to try all type of food and enjoys live music.


Collapse Company

   Formulating novel antimicrobial polymers.

Exsponge Inc. is a chemical company that formulates novel antimicrobial polymers for incorporation into a variety of applications.

Team

Tyler Poore (Technical Director) – Tyler works on product formulations, product applications, patent strategies, as well as general research and development.

Tyler is a PhD student at Columbia University, studying organic chemistry and natural product synthesis. He obtained his M.S. in chemistry from Columbia in 2011. Tyler was also a participant of the inaugural Innovation and Entrepreneurship program offered from Columbia University’s business school. His team was one of twelve out of over 100 to be accepted, where he learned the fundamentals of business strategy and entrepreneurship. Prior to Columbia, Tyler graduated from RPI, summa cum laude where he studied carbohydrate synthesis, biochemistry, and drug discovery.


Collapse Company

   Reducing complications resulting from blood transfusions.

Ex Vivo Dynamics is developing a non-invasive platform technology to reduce serious short and long term complications resulting from blood transfusions.

Team

Alan Perlstein (CEO) – Alan Perlstein M.S Is currently the founder and CEO of Ex Vivo Dynamics. He has over 10 years of extensive experience in biological and device engineering. He received his dual M.S from the Chemical and Biomolecular Engineering department of NYU-POLY. He has won the company many awards and prizes through multiple venture competitions in New York State in 2013.

Dr. Xi Huang (CSO) – Dr. Xi Huang is currently the Chief Scientific Officer at Ex Vivo Dynamics. He was an Associate Professor of Medicine and Environmental Medicine at New York University School of Medicine for over 12 years.Dr. Huang received his Ph.D. in Toxicology and Applied Pharmacology from University of Paris VII, France, and completed his post-doctoral training in Molecular Toxicology at New York University School of Medicine. He has published over 70 journal articles and book chapters and has received over $10 million in government grants.

Daisy Lobo (CAO) – Daisy Lobo M.S (2014) is currently the CAO of Ex Vivo Dynamics. She has 6 years of experience in Biotechnology.She is finishing her Masters at NYU-POLY.



Collapse Company

   Developing mitochondrial DNA based biomarkers for cancer and developmental disorders.

The mitochondrial genome (mtDNA) is the last frontier in this age of genomics. Mitochondria are implicated in developmental disorders and the development of resistance of cancer to chemotherapies. Girihlet will be developing kits, based on technology we have developed in an academic lab, to sequence the mtDNA efficiently, rapidly and inexpensively. We will also be developing the technique for research and clinical applications, in collaborations with academic labs.

Team

SONY DSC

Ravi Sachidanandam (Founder) – Ravi is a prolific researcher with over 85 published papers, spanning fields including small RNA biology, piRNAs in the germline, DNA methylation, mRNA splicing, bioinformatic tools, deep-sequencing techniques, cancer biology, human genetics and virology. At Mount Sinai, he also established the deep-sequencing core facility and developed several novel bioinformatic tools and wet-bench techniques for deep sequencing that have resulted in two patents. One on small RNA sequencing has been exclusively licensed and the other, on mtDNA sequencing, is the focus of Girihlet.

Collapse Company

   Transforming complex biology into practical solutions.

Gray Box Biology LLC was created to provide academic and commercial life science researchers with specialized teams of experts from various fields. The teams are formed from the large and diverse pool of highly trained scientists who live in New York City. We build these teams to meet the specific needs of our clients, which can range from simple validation of an ELISA assay or conducting preclinical animal studies.

Our latest project is the development of a prototype medical device which will operate in low resource areas (no electricity or running water) to diagnose the presence of drug-resistant tuberculosis in patients. The device, nicknamed the “Bronx Box 2.0”, was conceived by Dr. William R Jacobs of the Albert Einstein College of Medicine, and has the potential to reduce the mortality caused by the rapid emergence of drug-resistant tuberculosis.

Team

SONY DSC

Larry Leung (COO) – Dr. Leung graduated from Case Western Reserve University with a BS in Biomedical Engineering. From there, he shifted his focus from engineering to biology and obtained a PhD in biochemistry at The City University of New York. After work in the fields of cell biology (Weill Medical School of Cornell University) and viral immunology (Mt Sinai School of Medicine), Dr. Leung started Gray Box Biology LLC with the goal of tapping the immense scientific talent in New York to bring broad, yet detailed knowledge and expertise to private and academic research institutions.

Collapse Company

   Re-inventing allergy diagnostics.

Immunovent, LLC is an allergy diagnostics company that is developing the Local Allergy Mucosal Brush (LAMB) test. LAMB-Dx is the first local allergy test that can accurately diagnose the significant number of both airborne and food allergies that are currently undetected by traditional allergy testing methods. Moreover, LAMB-Dx is projected to have particular utility as a companion diagnostic to antigen-specific immunotherapy (AIT), the only curative treatment modality for allergic disease. The rapid and minimally invasive LAMB-Dx does not involve needles, making it ideal for the pediatric population.

Team

SONY DSC

Kate Rochlin (Chief Science Officer) – Ms. Rochlin is a PhD candidate at Weill Cornell Graduate School in NYC. She has expertise in cell and molecular biology and has been working in early stage technology commercialization through the Entrepreneurship Lab program with the NYCEDC.



SONY DSCErick Berglund, PhD (CEO) – Dr. Berglund received his MS from B.U. School of Medicine, followed by a PhD in biochemistry from Goethe University in Frankfurt, Germany. Dr. Berglund has held professional positions in business development, licensing, IP management, and marketing both within larger organizations as well as in start-up bioventure settings.



SONY DSCMichael Nelson, JD (CFO) – Michael graduated from Cornell University and received his J.D. from New York University School of Law. He is a managing director at Westwood Capital and previously was CFO of an early stage healthcare company, was an analyst at Barclays Capital and ING, and practiced law at Willkie Farr & Gallagher and Dewey Ballantine.



SONY DSCWilliam Reisacher, MD (Chief Medical Officer) – William received his medical degree from the Mount Sinai School of Medicine. He is an Associate Professor and the Director of Allergy within the Department of Otolaryngology-Head and Neck Surgery at Weill Cornell Medical College.


Collapse Company

   Accelerating the pace of research through innovative small animal imaging and analysis.

Founded and directed by Drs. Alexander Klose and Neal Paragas in 2012, InVivo Analytics, is a small animal optical imaging innovation company with an exclusive patented software and hardware suite, InVivoPLOT. This sophisticated system transforms current small animal optical imaging platforms into devices that can acquire quantitative 3D images. InVivoPLOT is designed to seamlessly incorporate into current drug discovery and development systems. InVivo Analytics offers custom image analysis services and consulting for all small animal optical imaging projects.

Team

SONY DSC Neal Paragas, PhD (Founder) – Neal has over ten years experience in modeling human disease in small animals using bioluminescence, animal genetics, and surgical methods. He is the author of over 15 peer-reviewed publications and book chapters. At InVivo Analytics, Dr. Paragas focuses on Preclinical Imaging Contract Research including consultation on animal models and experimental design. In 2010 he earned his Ph.D. in Metabolic Biology with Distinction from Columbia University and was the Dean’s Award Recipient for Excellence in Research. Currently Dr. Paragas has an appointment as an Instructor in Medical Sciences at Columbia University where he develops small animal models of human disease for molecular imaging. During his post-doctorate work at Columbia University he developed a bioluminescent reporter mouse which demonstrated the kinetics of a novel kidney biomarker which has been a highly cited publication in the journal Nature Medicine. Dr. Paragas’ work has earned him over a million dollars in grants and awards from the NIH and pharmaceutical industry.

SONY DSCAlexander Klose, PhD (Founder) – Alex earned a PhD in Physics in 2001 and has published over 30 journal articles and book chapters in radiation transport, inverse scattering problems, computational modeling, and molecular imaging. His efforts at InVivo Analytics focus on the development of image reconstruction software and hardware for bioluminescence imaging. Dr. Klose also serves as an Assistant Professor of Radiology at Columbia University and has been awarded research funding from the Ernst Schering Foundation, the Irving Institute for Clinical and Translational Research, and the National Institutes of Health.
Collapse Company

   Inventing microfabricated devices for human health diagnostics.

Junco Labs was founded to translate microfabrication technologies to products that improve human health. The company is currently developing handheld “lab-on-a-chip” devices that can perform rapid and inexpensive diagnostic tests at the point of care.

Collapse Company

   Proving clients personalized services for the measurement of microRNA.

Mirna Analytics provides personalized service to researchers in medicine and veterinary medicine for the measurement of microRNA in body fluids, particularly plasma or sputum. MicroRNAs are small molecules made for short- and long-distance communication between cells. The concentration of these microRNAs in body fluids can indicate risk or protection from disease, and some microRNAs are also useful as disease markers. MicroRNAs are highly similar between species, including humans and many pet, agricultural and exotic animals.

Full service provided by Mirna Analytics includes: Advice for study design, Begin lab work by isolating microRNA, Continue lab work by measuring microRNA levels, Determine and interpret results.

We anticipate that our first clients will come from research laboratories in pulmonary medicine or microbiology. Mirna Analytics will be built stepwise based on customer demand. We are seeking funding from the STTR / SBIR NIH grant program and from the Bill Gates Foundation. The customers and partners of Mirna Analytics are anticipated to be based in New York City and also in and outside of the US. Mirna Analytic’s aim is to serve the research, medical and veterinary communities.

Team

Gabriele Grunig, MD, PhD (President) – Dr. Grunig received a Veterinary Medicine degree (University of Zurich) and Ph.D. in Immunology (Cornell University, Ithaca, NY). She performed postdoctoral work in veterinary medicine at the University of Zurich and in the biomedical sciences at DNAX Research Institute, Palo Alto, and UCSF, San Francisco. Dr. Grunig is currently Professor at the Department of Environmental Medicine, NYU Medical Center, and the founder and president of Mirna Analytics.

Dr. Grunig’s goal is to translate basic science findings to clinical applications. Mirna Analytics serves this goal by providing full service for the determination of biomarkers of risk for disease, progression of disease, or as disease marker. Mirna Analytics focuses on microRNA because they are stable molecules of cellular communication, and they are highly similar between species, including humans, and animals (e.g. dogs, cats, horses, cows).

Scott Kahn, Ph.D – Dr. Kahn is scientific advisor for Mirna Analytics. Dr. Kahn has more than 30 years of experience in academic (Columbia University) molecular biology research with the goal to discover new biomarkers and therapies. Currently more than 3 years of experience as chief scientific officer of for-profit (Oncostem) and advisor of non-profit (e.g. Biomarkers Council; International Cancer Advocacy Network) organizations. Drs. Grunig and Kahn have collaborated for 7 years, working in adjacent laboratories at Columbia University.

Katelin Jackson – Katelin Jackson was awarded a Bachelors of Science at Cornell University in 2012. 2012- 2013 she was an Assistant Research Scientist at NYU Medical Center in Dr. Grunig’s Lab, working on molecular biology studies including PCR and genotyping. She is now Research Scientist (part time) for Mirna Analytics.



Collapse Company

   Developing oral small molecule drugs for hematology and oncology.

Multimodal Solutions is an emerging biotechnology company, focused on developing oral therapeutics to treat disease.

Team

Michael Isaacman, PH.D. (Founder and Chief Scientist) – Dr. Isaacman received his Ph.D. from the University of California, Santa Barbara. His research focused on the synthesis and self-assembling dynamics of silicone-based amphiphilic block co-polymers. Michael is an expert in silicone chemistry and has pioneered novel methodologies for the design & fabrication of silicone polymers for use in the drug delivery and personal care. Michael has published in the fields of natural product synthesis, chiroptical metal detection, and polymer chemistry.



Collapse Company

   Developing novel cancer therapies targeting currently unaddressed tumor drivers.

Oncostem Biotherapeutics is a drug discovery company dedicated to the health and welfare of individuals who are living with cancer. Bottom line, in the United States, one person dies from cancer every minute, over 500,000 individuals per year. Worldwide, one person dies every eight seconds, over 3,000,000 individuals per year. We can, and must do better in providing more efficacious treatment options for individuals with cancer.

Oncostem Biotherapeutics was established by Rudolph E. Willis, MD, a globally renowned oncologist, and Scott M. Kahn, Ph.D., an expert in oncology, translational biology, cellular signaling and a pioneer in the field of oncogene addiction. Our aim is to develop novel targeted therapies against proven oncogenic drivers that remain orphan to currently available therapies. Our lead targets fulfill a set of stringent requirements, and display all desired characteristics of being tumor drivers- they are the focus of causative genetic lesions in tumors, they have been demonstrated experimentally and biologically to fulfill the properties of tumor drivers, as opposed to being bystanders, and their inhibition suppresses cell growth and/or kills cancer cells that are otherwise driven by their presence.

The ultimate goal of Oncostem Biotherapeutics is to develop a panel of novel targeted therapies that will have a major positive impact on the treatment and survival of individuals with cancer.

Team

Rudolph E. Willis, M.D. (President and CEO) -Dr. Willis is a founding member of OncoStem Biotherapeutics. He is a theoretical biologist with over 28 years of experience in all aspects of cancer therapy and research. He is the author of the foundational theoretical biology work that serves as the basis for the development of a new class of targeted anti-cancer drugs.

He has served as the Director of the Clinical Trials Subunit at Washington University School of Medicine and participated in innumerable clinical trials. He is the author of several scientific and clinical papers in oncology and molecular biology. He is a member of American Society of Clinical Oncology, American Society for Cell Biology, and a member of the NIH Alumni Association. Currently, he is an Assistant Professor of Medicine at Drexel College of Medicine in Philadelphia, and is earning a MS degree in Bioinformatics from John Hopkins University. He is on the editorial review board of Current Cancer Drug Targets. He belongs to MENSA.

Scott M. Kahn, Ph.D. (Chief Scientific Officer) – Dr. Scott M. Kahn brings over 30 years of expertise executing and directing top-level projects in academia and industry. Dr. Kahn combines a deep understanding of oncology, personalized medicine, translational research, biomarkers, and biomedical research, with a high technical acumen and an acute mind for business development. He has directed projects alongside global thought leaders, worldwide industry and academic research groups, and cross-functional teams.

Dr. Kahn completed his postdoctoral studies in the Herbert Irving Comprehensive Cancer Center at Columbia University, received his Ph.D. degree in Biochemistry and Molecular Biology from SUNY@ Stony Brook, and his B.A. degree with double majors in Chemistry and in Biochemistry from Brandeis University.

Collapse Company

   Supplying the highest quality neurons to the world’s researchers.

We have developed a proprietary technique to cryogenically preserve primary cells, allowing neuroscientists around the globe to outsource that work to us, freeing their time and budget to spend on real science. Rodent neurons and astrocytes are shipped worldwide (all cell types are available by custom order). Our product is morphologically superior, and results in a cost savings of up to 90%. We offer a 100% Satisfaction Guarantee.

Team

Spencer Adler (Chairman and CEO) – Spencer is an attorney, entrepreneur, and investor, with a history working with disruptive technologies involving the environment, energy, and more recently biology. He created SynBio Investors, LLC to back the first incubator of synthetic biology companies, called Launchpad, on the NASA campus in Silicon Valley. In New York City, he created the Bioeconomy Supper Club and the Bioeconomy Fundamentals Course. He is also co-producer of the climate change film The Island President (with music by Radiohead).

Daniel Rootenberg (CFO) – Daniel Rootenberg is our CFO, having most recently served as VP of FInance for Shutterstock as it grew from a $200M private company, through IPO, to its present $2.4B market cap. He previously was CFO of WeightWatchers.com through its acquisition for $650M, and is the equivalent of a Certified Public Accountant in South Africa.



Collapse Company

   Advancing osteoarthritis treatment through minimally invasive therapies to stimulate cartilage cell growth.

Rho Nanodiagnostic Corporation is a new biotechnology company founded with the intent to produce a therapeutic modality for the treatment of moderate osteoarthritic disease. Our company springs from the experience of its president who is a practicing orthopedic surgeon with a passion for advancing osteoarthrits treatment. Our goal is to introduce minimally invasive therapies for osteoarthritis that are based on molecules that stimulate cartilage cell growth and motility.

Erica Rowe Urquhart, M.D., Ph.D.(President) – Erica is an orthopedic surgeon whose practice focuses on the treatment of arthritic conditions. A graduate of Harvard College, with a Bachelor of Science degree in Biomedical Engineering, Dr. Urquhart obtained her M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. The formation of Rho Nanodiagnostic Corporation represents a culmination of Dr. Urquhart’s aspiration to translate molecular guidance cues to clinical therapies.



Marc W. Urquhart, M.D. Marc is an orthopedic surgeon who specializes in the treatment of upper extremity and sports medicine injuries. Having performed many cartilage transplantation procedures, Dr. Marc Urquhart would like to develop a treatment for patients who go on to develop moderate-stage osteoarthritis. Dr. Urquhart holds a Bachelor of Science degree in Biology from Iowa State University and received his M.D. from the Johns Hopkins University School of Medicine.


Collapse Company

   Developing therapeutics to treat diseases caused by imbalances in the gut microbial ecosystem.

Symbiotic Health, Inc. is a team of clinicians and scientists dedicated to commercializing microbiome-based therapeutics and diagnostics. The microbiome, an ecosystem of symbiotic bacteria, is an integral part of the healthy human body. Antibiotic-induced injury to the gut microbiome can lead to dangerous infections, especially with Clostridium difficile. The Centers for Disease Control considers this infection, which can cause severe chronic diarrhea, as an “immediate public health threat that requires urgent and aggressive action” (www.cdc.gov/drugresistance/threat-report-2013).

Our therapeutics re-balance the gut microbiome to treat Clostridium difficile infection. Building on this proof-of-concept indication, we will develop microbiome medicine to shift clinical paradigms with powerful, practical and cost-effective solutions to critical public health problems.

Team

Gerard Honig, PhD (Founder & Director of Operations) – Gerard is a research scientist with a passion for applying cutting-edge research to meet real-world problems. Gerard, a native New Yorker, received his BA in Biology from Columbia University and his PhD in Neuroscience (2009) from University of California San Francisco. He has trained in immunology, pathogenesis and microbiome research in the laboratories of Betty Diamond (Feinstein Institute) and Dan Littman (NYU). He has extensive experience in a wide range of scientific approaches and is very excited to apply this experience as part of the Harlem Biospace community. Gerard is a student of Japanese martial arts at the Kokushi Budo Institute and also enjoys building bikes, kayaking and DJing.

Bruce Hirsch, MD (Chief Medical Officer) – Bruce has been serving the community of the New York metropolitan area as a physician for over 30 years. Bruce received his MD from Cornell University and trained in geriatrics and infectious disease at North Shore University Hospital, Cornell and Albert Einstein. Currently, he is attending physician and assistant professor in the Infectious Disease Division of the North Shore LIJ Health System. Bruce worked through the HIV crisis from its earliest manifestations in New York and has maintained a strong interest in HIV. More recently, he has pioneered the use of bacterial replacement therapy for the treatment of gut infections within the North Shore LIJ Health System. He has a long-standing interest in innovative therapeutics, having chaired the North Shore LIJ Committee on Pharmacy and Therapeutics, and holds a patent for an infection control device.

Andrew Sczesnak (Director of Bioinformatics) – Andrew has several years of experience designing and implementing bioinformatics pipelines, especially for the analysis of microbial communities with genome and metagenome sequencing. At New York University, he sequenced and analyzed the genome of well-known segmented filamentous bacteria (SFB), an immune-modulating commensal bacterium. He was also a lead author on a recent study demonstrating the strikingly high abundance of a single gut microbe in sufferers of rheumatoid arthritis. Andrew is currently a graduate student at the University of California, San Francisco where he is a National Science Foundation fellow studying Bioinformatics and Computational Biology.

At Symbiotic Health, Inc., he manages all bioinformatics work, designing computational experiments and interpreting results for our team of biomedical researchers.

Collapse Company

   Developing nanoparticles of omega-3 fatty acids for diagnosis and treatment of inflammatory diseases.

Theranostica is a biotechnology start-up aiming to develop novel approaches of using omega-3 fatty acids nanoparticles towards the diagnosis and treatment of chronic inflammatory diseases. This patent-pending technology enables the rapid target delivery of polyunsaturated lipid compounds with anti-inflammatory and pro-resolving properties to organs or tissues in the body (i.e. an inflamed atherosclerotic plaque or a region of myocardial damage). Ongoing research seeks to refine this technology and to expand on its potential in detecting inflammation within the body. Ultimately, a “theranostic” tool is envisioned to detect, treat and monitor inflammatory diseases ranging from cardiovascular disorders to cancer.

Team

Henry Wu, MD (Founder and CEO) – Dr. Wu is a physician scientist who received his medical training at Weill Cornell Medical Center, Columbia Presbyterian Hospital, and Brigham and Women’s Hospital. He is an expert in non-invasive multi-modality cardiovascular imaging utilizing ultrasound, magnetic resonance and optical methods. He was previously on faculty at Columbia College of Physicians and Surgeons with research focus on the role of inflammation in chronic diseases such as atherosclerosis and cancer. His research had received funding from the National Institutes of Health. In 2008, Dr. Wu left academia to develop a ultrasound delivery method of targeting omega-3 fatty acids to the heart as anti-inflammatory treatment. This novel technology has recently received conditional approval from the United States Patent Office.

Collapse Company

   Channeling clinical experience to develop innovative therapies for keloid disorder.

Tirgan Biopharmaceuticals was established in September 2011 by Dr. Michael H Tirgan, a board certified medical oncologist with over 15 years of full time medical practice and over 5 years of full time pharmaceutical industry experience in oncology drug development. For the past five years, Dr. Tirgan’s medical practice has primarily focused on providing treatment to patients with keloid disorder. He is well aware of the current treatment and research landscape of this debilitating skin condition and the urgent need for developing effective therapeutics for this disorder.

Team

Michael H. Tirgan, MD ( President) – Dr. Tirgan is a board certified medical oncologist. After working full time for 15 years and treating cancer patients on a day to day basis, in 2007, he started working with pharmaceutical industry as medical director in oncology drug development. With over 5 years of experience in design and conduct of clinical trials, Dr. Tirgan is quite familiar with the regulatory processes as well as paths to obtaining regulatory approval for new medicinal products.

While working full time with pharma, Dr. Tirgan maintained a limited medical practice with focus on Keloid Disorder. Since 2008, he has treated more than 700 patients with this skin condition. Dr. Tirgan left pharma in November 2011, to focus his attention on his medical practice and his own research in keloid disorder. He has five IRB approved keloid studies.

Dr. Tirgan has been an attending physician with St. Luke’s Roosevelt Hospital in New York since 2003. He is an Instructor in Medicine with Columbia College of Physicians and Surgeons and associate attending physician at Rockefeller University Hospital with focus on keloid disorder. Currently, in his medical practice, Dr. Tirgan provides medical care to about 40-50 keloid patients per week.

Nadereh Nouhi (CEO) – Nadereh is an independent consultant, with 27 years of professional experience, providing services in the financial and business strategy areas to various organizations and enterprises in New York City and other national and international localities. In the not-for-profit sector, her clients have included micro-finance institutions and affiliates of the Women’s World Banking, mainly in Latin America and Kenya. In the for-profit sector, they include start-up and existing companies in various industries including healthcare and biomedical.

Prior to starting her consulting practice, Nadereh worked at the NYC Financial Services Corporation (NYC FSC), currently known as NYC Economic Development Corporation. She structured and executed corporate and real estate financings for companies in various industries, was on the team developing new financing instruments, including a start-up loan program and a credit-enhanced bond program. She also managed the composite bond program, as well as defining economic development policies in conjunction with special corporate initiatives and specific requirements.

She obtained her Bachelors Degree from University of Rochester in 1983 and her MBA in Finance and Accounting from Columbia University in 1985.


Madhav Kamat, Ph.D, R.Ph (Vice President for Formulation and Manufacturing) – Dr. Kamat is an expert in the field of nano/micro suspension technology and sustained release injectable pharmaceuticals. He has been involved in the product/process development (small molecule and biologics), lyophilization, scale-up/technology transfer, and sterile manufacturing of more than 20 injectable commercial products. He is well-recognized expert in the fields of lyophilization, nano-suspension technology, aseptic technology, and other sterile manufacturing processes. He has been active in various initiatives by US-FDA and American Association of Pharmaceutical Scientists (AAPS). His recent interests are formulation and process development of biologics products and IV injectable products of water-insoluble drugs.

Dr. Kamat received his B. Pharm and M. Pharm from Bombay (Mumbai) University and Ph.D. from the College of Pharmacy at the University of Kentucky in Lexington. He worked at Bristol-Myers Squibb Company for the last seventeen years, and most recently as a Director in Manufacturing Technology of Sterile/Biologics products. Prior to BMS, Dr. Kamat worked at Centocor, J&J, and Somatogen. He is also a Registered Pharmacist in the States of Pennsylvania and New Jersey.

With over 25 years of sound industrial experience in large pharmaceutical companies specializing in the area of injectable products and processes, Dr. Kamat is leading development of our innovative injectable products for treatment of keloid disorder.


Collapse Company

Join the Community List

We hope to see you at classes or events soon.